Palliative CareARREVE-3NCT07368010
End-of-life Care in Mechanically Ventilated Patients: Impact of a Comprehensive Palliative Care Protocol in the Intensive Care Setting
A study testing Protocol for palliative care and life-support withdrawal in people with Palliative Care and Withdrawal of Life Support, run by Nantes University Hospital at 1 site in France.
Trial summary
The ARREVE-3 trial will evaluate whether a structured palliative care protocol can improve end-of-life management for mechanically ventilated ICU patients in whom a decision to withdraw life-sustaining therapies has been made. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Palliative Care, Withdrawal of Life Support, Intensive Care Medicine
- What is being tested?
- Protocol for palliative care and life-support withdrawal
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 720 participants
- Where
- 1 siteFrance
- Study dates
- 10 Jan 2026to 10 Jan 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient:
- Age ≥ 18 years
- ICU admission for more than 48 hours
- Receiving invasive mechanical ventilation
- A documented decision to withdraw life-sustaining therapies, made through a multidisciplinary collegial process and communicated to the designated surrogate decision-maker, family, or relatives
- At least one visit from a relative prior to the decision to withdraw life-sustaining therapies
Show all 11Show fewer
- Provision of informed consent for study participation, or, if the patient lacks decision-making capacity, consent obtained from a relative or legally authorized representative
- Relative:
- Age ≥ 18 years
- Has received at least one medical update regarding the patient's clinical status from an ICU physician prior to the decision to withdraw life-sustaining therapies
- Has provided informed consent for study participation
Who cannot join
- Patient:
- Presence of a tracheostomy
- Brain death or involvement in an organ donation procedure
- Absence of any visit from a relative
- Subject to legal guardianship or other legal protection measures
- Incarcerated patient
Show all 11Show fewer
- Participation in another interventional research study focused on end-of-life care
- Pregnant or breastfeeding woman
- Relative:
- Inability to understand or speak French
- Subject to legal guardianship or other legal protection measures
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Jean REIGNIER, MD Professor contact
France1 site
CHU Nantes
Nantes, 44
Amélie SEGUIN, MD, 0253482240 ext. +332, amelie.seguin@chu-nantes.fr
About this study
Official title: End-of-life Care in Mechanically Ventilated Patients: Impact of a Comprehensive Training to Palliative Care in the Intensive Care Setting. A Multicenter Cluster Randomised Trial
The ARREVE-3 trial will evaluate whether a structured palliative care protocol can improve end-of-life management for mechanically ventilated ICU patients in whom a decision to withdraw life-sustaining therapies has been made. This cluster-randomized controlled trial compares protocol-based care with usual practice across participating centers. The intervention includes comprehensive guidance on symptom management, sedation, nursing care, withdrawal procedures, and family support, supported by standardized staff training. The primary endpoint is adherence to recommended end-of-life practices, while secondary outcomes assess patient comfort, communication with relatives, and the impact on families and healthcare professionals
Read the detailed description
Among ICU patients who die after a decision to withdraw life-sustaining therapies, most are receiving mechanical ventilation (MV). Withdrawal of MV may cause discomfort, and end-of-life practices can have a lasting impact on both families and healthcare professionals. Despite international guidelines and recent legislative changes in France, end-of-life practices in the ICU remain highly variable, indicating substantial opportunities for improvement in patient comfort-focused management.
The ARREVE-3 trial aimes to determine whether a structured palliative care protocol for mechanically ventilated patients undergoing withdrawal of life-sustaining therapies improves the quality of the dying process. Developed in collaboration with palliative care specialists, a psychologist, and a sociologist, the protocol provides standardized guidance on pharmacological and non-pharmacological interventions, including symptom assessment tools, sedation strategies, nursing care, and procedures for withdrawal of life-sustaining treatment. Structured recommendations for support of relatives are also included.
ARREVE-3 is a pragmatic, interventional, cluster-randomized controlled trial, with participating ICUs being unit of randomization to minimize contamination between study arms. ICUs randomized to the intervention arm will apply the palliative care protocol, whereas control ICUs will continue to follow usual care. Physicians and nurses in intervention ICUs will receive standardized training from the coordinating team, complemented by a video-based educational module. Designated local champions within each ICU will support implementation and adherence.to the protocol.
The primary endpoint is adherence to the protocol for end-of-life care. Secondary outcomes include patient comfort, quality of communication with relatives, and the impact of the end-of-life process on relatives and healthcare professionals.
- Conditions
- Palliative Care, Withdrawal of Life Support, Intensive Care Medicine, Sedation, Dying Process
- Being tested
- Protocol for palliative care and life-support withdrawal
- Keywords
- End of life, intensive care medicine, mechanical ventilation, organ support, withdrawal, life support, sedation, palliative care
- Medical subject headings
- Death
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Protocol for palliative care and life-support withdrawalOther
In the intervention group, end-of-life care will be provided in accordance with the study protocol, which specifies pharmacological management, nursing care, management of life-sustaining organ support, procedures for the assessment of comfort and pain, and support for relatives. Medical and nursing staff in intervention centers will receive on-site, face-to-face training on the care protocol within each ICU. An instructional video detailing the protocol will also be available.
| Study group | Role | What they receive |
|---|---|---|
| Palliative care protocol | Experimental | Protocol for life-support withdrawal and palliative care during the withdrawal process Receives: Other: Protocol for palliative care and life-support withdrawal |
| Usual Care | No intervention | Withdrawal of life support at the end of life will be performed according to the usual practices of the participating ICUs |
What is being measured
The primary outcome is the main question the study is designed to answer.
To assess whether, compared with usual care, the implementation of a palliative care protocol for mechanically ventilated patients-combined with dedicated staff training-improves adherence to guidelines.
Proportion of patients receiving adequate sedation (RASS-5 within one hour before withdrawal of life-sustaining therapies) and withdrawal of mechanical ventilation
Measured: From 1h before the date of life-support withdrawal to date of ICU discharge or death, whichever came first, assessed up to 28 days
Secondary outcomes (31)
Evaluation of Sedation
Maximum rate of continuous infusion of each sedative agent administered (within 1 hour before the first withdrawal of life sustaining therapies and death)
Measured: From 1h before the date of life-support withdrawal to date of ICU discharge or death, whichever came first, assessed up to 28 days
Evaluation of Sedation
Number of sedative boluses and number of dose escalations of continuous sedation between inclusion and death
Measured: From 1h before the date of life-support withdrawal to date of ICU discharge or death, whichever came first, assessed up to 28 days
Proportion of Patients Receiving Medications Other Than Sedatives
Proportion of patients receiving neuromuscular blocking agents, scopolamine, paracetamol (acetaminophen), or antiemetic agents.
Measured: From 1h before the date of life-support withdrawal to date of ICU discharge or death, whichever came first, assessed up to 28 days
Administration of neuromuscular blocking agents
Proportion of patients receiving neuromuscular blocking agents
Measured: From 1h before the date of life-support withdrawal to date of ICU discharge or death, whichever came first, assessed up to 28 days
Administration of scopolamine
Proportion of patients receiving scopolamine
Measured: From 1h before the date of life-support withdrawal to date of ICU discharge or death, whichever came first, assessed up to 28 days
Administration of paracetamol (acetaminophen)
Proportion of patients receiving paracetamol (acetaminophen)
Measured: From 1h before the date of life-support withdrawal to date of ICU discharge or death, whichever came first, assessed up to 28 days
Administration of Receiving antiemetic agents
Proportion of patients receiving antiemetic agents
Measured: From 1h before the date of life-support withdrawal to date of ICU discharge or death, whichever came first, assessed up to 28 days
The Semi-Lateral (¾ Lateral) Position
Proportion of patients positioned in the semi-lateral (¾ lateral) position 1 hour before treatment withdrawal and 1 hour before death
Measured: From 1h before the date of life-support withdrawal to date of ICU discharge or death, whichever came first, assessed up to 28 days
Life-Sustaining Organ Support Management
Proportion of patients receiving dialysis, vasoactive drug and/or ECMO at inclusion and at death
Measured: From inclusion to date of ICU discharge or death, whichever came first, assessed up to 28 days
Life-Sustaining Organ Support Management
Proportion of patients in whom all life-sustaining therapies are discontinued before death
Measured: From inclusion to death, assessed up to 28 days
Life-Sustaining Organ Support Management
Proportion of patients in whom all life-sustaining therapies are withdrawn concomitantly
Measured: From inclusion to date of ICU discharge or death, whichever came first, assessed up to 28 days
Life-Sustaining Organ Support Management
Proportion of patients whith immediate extubation
Measured: From inclusion to date of ICU discharge or death, whichever came first, assessed up to 28 days
Time from Inclusion to Extubation
Time interval between inclusion and extubation
Measured: From inclusion to date of extubation, assessed up to 28 days
Assessment of Sedation
Proportion of patients with a Richmond Agitation-Sedation Scale (RASS) score of -5 or > -4 (≥ -3) 1 hour before withdrawal of the first life-sustaining therapy (mechanical ventilation, vasopressors, or ECMO) and 1 hour before extubation
Measured: From inclusion to date of ICU discharge or death, whichever came first, assessed up to 28 days
Assessment of Pain Management
Higher Behavioral Pain Scale (BPS) score 1 hour before withdrawal of the first life-sustaining therapy (mechanical ventilation, vasopressors, or ECMO); BPS min = 3, max = 12; Higher scores correlate with increased pain intensity.
Measured: From 1h before the date of life-support withdrawal to date of ICU discharge or death, whichever came first, assessed up to 28 days
Assessment of Comfort Management
Proportion of patients with airway secretion scores of 3 or 4
Measured: From 1h before the date of life-support withdrawal to date of ICU discharge or death, whichever came first, assessed up to 28 days
Assessment of Comfort Management
Proportion of patients with more than one gasp (≥ 2)
Measured: From 1h before the date of life-support withdrawal to date of ICU discharge or death, whichever came first, assessed up to 28 days
Assessment of Communication with Relatives
Proportion of relatives who had at least three meetings with ICU caregivers
Measured: From inclusion to date of ICU discharge, assessed up to 28 days
Assessment of Communication with Relatives
Proportion of meetings conducted jointly by a senior physician and a nurse
Measured: From inclusion to date of ICU discharge, assessed up to 28 days
Assessment of Communication with Relatives
Proportion of relatives who had a meeting with a psychologist
Measured: From inclusion to date of ICU discharge, assessed up to 28 days
Assessment of Conflicts
Level of conflicts between ICU healthcare givers and relatives, as rated on a 0-10 Likert scale. A higher score indicates a more intense conflict.
Measured: From inclusion to date of ICU discharge, assessed up to 28 days
Assessment of Conflicts
Level of conflicts between among healthcare professionals, as rated on a 0-10 Likert scale. A higher score indicates a more intense conflict.
Measured: From inclusion to date of ICU discharge, assessed up to 28 days
Assessment of Conflicts
Level of conflicts between among relatives, as rated on a 0-10 Likert scale. A higher score indicates a more intense conflict.
Measured: From inclusion to date of ICU discharge, assessed up to 28 days
Assessment of Quality of Dying by Relatives
Quality of Dying and Death questionnaire (QODD-1) assessed 1 month after death, as rated on a 0-10 Likert scale. Higher scores correlate with a more satisfactory level of care.
Measured: From inclusion to 1 month after death of the patient
Anxiety and Depression in Relatives
Hospital Anxiety and Depression Scale (HADS) assessed 1, 3, 6, and 12 months after death. HADS min = 0, max = 42; Higher scores correlate with increased risk of anxiety and depression.
Measured: From inclusion to 1, 3, 6, and 12 months after the death of the patient
Post-Traumatic Stress Disorders in Relatives
Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5) assessed 1, 3, 6, and 12 months after death. PCL-5 min = 0, max = 80; Higher scores correlate with increased risk of posttraumatic stress.
Measured: From inclusion to 1, 3, 6, and 12 months after the death of the patient
Prolonged Grief in Relatives
Prolonged Grief Disorder scale (PG-13) assessed 12 months after death. PG-13 min = 4, max = 48; Higher scores correlate with increased risk of prolonged grief.
Measured: From inclusion to 12 months after the death of the patient
Assessment of Quality of Dying by Healthcare Professionals
Quality of Dying and Death questionnaire (QODD-1), as rated on a 0-10 Likert scale. Higher scores correlate with a more satisfactory level of care.
Measured: After the death of the patient, assessed up to 28 days
Psychological Impact on Healthcare Professionals
Measure of Moral Distress for Healthcare Professionals (MMD-HP). MMD-HP min = 0, max = 432; Higher scores correlate with increased risk of moral distress.
Measured: After the death of the patient, assessed up to 28 days
Impact on ICU Organization and Staff
Perceived Stressors in Intensive Care Units (PS-ICU) assessing burnout at the end of the inclusion period. PS-ICU min = 0, max = 104; Higher scores correlate with increased risk of stress at work.
Measured: Up to 2 years
Impact on ICU Organization and Staff
Maslach Burnout Inventory (MBI) assessing burnout at the end of the inclusion period. MBI min = 0, max = 132; Higher scores correlate with increased risk of burnout.
Measured: Up to 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jan 2026
- Study start10 Jan 2026 (estimated)
- Primary completion10 Jan 2028 (estimated)
- Study completion10 Jan 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Palliative CareStudies of the same condition, open and under way.
- More trials run by Nantes University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Cluster randomized controlled trial
- Masking
- None (open label)
- Enrolment
- 720 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Nantes University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- University of Burgundy, Centre Hospitalier Universitaire de Saint Louis APHP, University Hospital, Tours
- Responsible party
- Sponsor
- Investigators
- Amélie SEGUIN, MD, Principal investigator, Nantes University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07368010
- Sponsor's protocol ID
- RC24_0575
- Acronym
- ARREVE-3
- Status last verified
- Jan 2026
- First submitted
- 19 Dec 2025
- Last updated
- 26 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 26 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- End-of-life Care in Mechanically Ventilated Patients: Impact of a Comprehensive Training to Palliative Care in the Intensive Care Setting. A Multicenter Cluster Randomised Trial
- ClinicalTrials.gov ID
- NCT07368010
- Acronym / sponsor ID
- ARREVE-3 / RC24_0575
- Conditions
- Palliative Care, Withdrawal of Life Support, Intensive Care Medicine, Sedation, Dying Process
- Keywords
- End of life, intensive care medicine, mechanical ventilation, organ support, withdrawal, life support, sedation, palliative care
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 720 participants (estimated)
- Lead sponsor
- Nantes University HospitalUniversity, hospital or other
- Collaborators
- University of Burgundy, Centre Hospitalier Universitaire de Saint Louis APHP, University Hospital, Tours
- Study start
- 10 Jan 2026 (estimated)
- Primary completion
- 10 Jan 2028 (estimated)
- Study completion
- 10 Jan 2029 (estimated)
- First posted
- 26 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The ARREVE-3 trial will evaluate whether a structured palliative care protocol can improve end-of-life management for mechanically ventilated ICU patients in whom a decision to withdraw life-sustaining therapies has been made. This cluster-randomized controlled trial compares protocol-based care with usual practice across participating centers. The intervention includes comprehensive guidance on symptom management, sedation, nursing care, withdrawal procedures, and family support, supported by standardized staff training. The primary endpoint is adherence to recommended end-of-life practices, while secondary outcomes assess patient comfort, communication with relatives, and the impact on families and healthcare professionals
Detailed description
Among ICU patients who die after a decision to withdraw life-sustaining therapies, most are receiving mechanical ventilation (MV). Withdrawal of MV may cause discomfort, and end-of-life practices can have a lasting impact on both families and healthcare professionals. Despite international guidelines and recent legislative changes in France, end-of-life practices in the ICU remain highly variable, indicating substantial opportunities for improvement in patient comfort-focused management.
The ARREVE-3 trial aimes to determine whether a structured palliative care protocol for mechanically ventilated patients undergoing withdrawal of life-sustaining therapies improves the quality of the dying process. Developed in collaboration with palliative care specialists, a psychologist, and a sociologist, the protocol provides standardized guidance on pharmacological and non-pharmacological interventions, including symptom assessment tools, sedation strategies, nursing care, and procedures for withdrawal of life-sustaining treatment. Structured recommendations for support of relatives are also included.
ARREVE-3 is a pragmatic, interventional, cluster-randomized controlled trial, with participating ICUs being unit of randomization to minimize contamination between study arms. ICUs randomized to the intervention arm will apply the palliative care protocol, whereas control ICUs will continue to follow usual care. Physicians and nurses in intervention ICUs will receive standardized training from the coordinating team, complemented by a video-based educational module. Designated local champions within each ICU will support implementation and adherence.to the protocol.
The primary endpoint is adherence to the protocol for end-of-life care. Secondary outcomes include patient comfort, quality of communication with relatives, and the impact of the end-of-life process on relatives and healthcare professionals.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Cluster randomized controlled trial
| Arm | Type | Receives |
|---|---|---|
| Palliative care protocol | Experimental | Other: Protocol for palliative care and life-support withdrawalProtocol for life-support withdrawal and palliative care during the withdrawal process |
| Usual Care | No intervention | –Withdrawal of life support at the end of life will be performed according to the usual practices of the participating ICUs |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Patient:
- Relative:
Key exclusion criteria (11 listed)
- Patient:
- Relative:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Protocol for palliative care and life-support withdrawalIn the intervention group, end-of-life care will be provided in accordance with the study protocol, which specifies pharmacological management, nursing care, management of life-sustaining organ support, procedures for the assessment of comfort and pain, and support for relatives. Medical and nursing staff in intervention centers will receive on-site, face-to-face training on the care protocol within each ICU. An instructional video detailing the protocol will also be available. | Other | Palliative care protocol |
Primary outcome
To assess whether, compared with usual care, the implementation of a palliative care protocol for mechanically ventilated patients-combined with dedicated staff training-improves adherence to guidelines.
Time frame: From 1h before the date of life-support withdrawal to date of ICU discharge or death, whichever came first, assessed up to 28 days
Proportion of patients receiving adequate sedation (RASS-5 within one hour before withdrawal of life-sustaining therapies) and withdrawal of mechanical ventilation
31 secondary outcomes
Evaluation of Sedation
Time frame: From 1h before the date of life-support withdrawal to date of ICU discharge or death, whichever came first, assessed up to 28 days
Evaluation of Sedation
Time frame: From 1h before the date of life-support withdrawal to date of ICU discharge or death, whichever came first, assessed up to 28 days
Proportion of Patients Receiving Medications Other Than Sedatives
Time frame: From 1h before the date of life-support withdrawal to date of ICU discharge or death, whichever came first, assessed up to 28 days
Administration of neuromuscular blocking agents
Time frame: From 1h before the date of life-support withdrawal to date of ICU discharge or death, whichever came first, assessed up to 28 days
Administration of scopolamine
Time frame: From 1h before the date of life-support withdrawal to date of ICU discharge or death, whichever came first, assessed up to 28 days
Administration of paracetamol (acetaminophen)
Time frame: From 1h before the date of life-support withdrawal to date of ICU discharge or death, whichever came first, assessed up to 28 days
Administration of Receiving antiemetic agents
Time frame: From 1h before the date of life-support withdrawal to date of ICU discharge or death, whichever came first, assessed up to 28 days
The Semi-Lateral (¾ Lateral) Position
Time frame: From 1h before the date of life-support withdrawal to date of ICU discharge or death, whichever came first, assessed up to 28 days
Life-Sustaining Organ Support Management
Time frame: From inclusion to date of ICU discharge or death, whichever came first, assessed up to 28 days
Life-Sustaining Organ Support Management
Time frame: From inclusion to death, assessed up to 28 days
Life-Sustaining Organ Support Management
Time frame: From inclusion to date of ICU discharge or death, whichever came first, assessed up to 28 days
Life-Sustaining Organ Support Management
Time frame: From inclusion to date of ICU discharge or death, whichever came first, assessed up to 28 days
Time from Inclusion to Extubation
Time frame: From inclusion to date of extubation, assessed up to 28 days
Assessment of Sedation
Time frame: From inclusion to date of ICU discharge or death, whichever came first, assessed up to 28 days
Assessment of Pain Management
Time frame: From 1h before the date of life-support withdrawal to date of ICU discharge or death, whichever came first, assessed up to 28 days
Assessment of Comfort Management
Time frame: From 1h before the date of life-support withdrawal to date of ICU discharge or death, whichever came first, assessed up to 28 days
Assessment of Comfort Management
Time frame: From 1h before the date of life-support withdrawal to date of ICU discharge or death, whichever came first, assessed up to 28 days
Assessment of Communication with Relatives
Time frame: From inclusion to date of ICU discharge, assessed up to 28 days
Assessment of Communication with Relatives
Time frame: From inclusion to date of ICU discharge, assessed up to 28 days
Assessment of Communication with Relatives
Time frame: From inclusion to date of ICU discharge, assessed up to 28 days
Assessment of Conflicts
Time frame: From inclusion to date of ICU discharge, assessed up to 28 days
Assessment of Conflicts
Time frame: From inclusion to date of ICU discharge, assessed up to 28 days
Assessment of Conflicts
Time frame: From inclusion to date of ICU discharge, assessed up to 28 days
Assessment of Quality of Dying by Relatives
Time frame: From inclusion to 1 month after death of the patient
Anxiety and Depression in Relatives
Time frame: From inclusion to 1, 3, 6, and 12 months after the death of the patient
Post-Traumatic Stress Disorders in Relatives
Time frame: From inclusion to 1, 3, 6, and 12 months after the death of the patient
Prolonged Grief in Relatives
Time frame: From inclusion to 12 months after the death of the patient
Assessment of Quality of Dying by Healthcare Professionals
Time frame: After the death of the patient, assessed up to 28 days
Psychological Impact on Healthcare Professionals
Time frame: After the death of the patient, assessed up to 28 days
Impact on ICU Organization and Staff
Time frame: Up to 2 years
Impact on ICU Organization and Staff
Time frame: Up to 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jan 2026.
- Individual participant dataSharing planned: Yes
Related trials for Palliative Care
Not yet recruitingObservational study
IN-TALK: Co-producing a Hospice Intimacy Support Toolkit in England
Communication About Intimacy Needs in Hospice and Palliative Care
Not yet recruitingPhase 2
Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
RecruitingPhase 1/2
Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction
Malignant Solid Neoplasm
Active, not recruiting
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
Liver Disease Chronic, End Stage Liver DIsease
Not yet recruiting
Comparing Radiotherapy Dose Strategies for Symptom Relief in Large Solid Tumors
Solid Tumor
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jean REIGNIER, MD Professor contact
Amélie SEGUIN, MD principal investigator
Nantes University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Protocol for palliative care and life-support withdrawal in people with Palliative Care and Withdrawal of Life Support, run by Nantes University Hospital at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 26 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Amélie SEGUIN, MD (02 53 48 22 40 ext. +332, amelie.seguin@chu-nantes.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To assess whether, compared with usual care, the implementation of a palliative care protocol for mechanically ventilated patients-combined with dedicated staff training-improves adherence to guidelines. (time frame: From 1h before the date of life-support withdrawal to date of ICU discharge or death, whichever came first, assessed up to 28 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jan 2026.